 |
|
|
| |
Absolute Survival Benefit of DAA Therapy in Hospitalized Patients with HCV-Related Cirrhosis: A Restricted Mean Survival Time Analysis (MIMIC-IV
|
| |
| |
AASLD 2026 Denver
Innocent Lutaya, MD1, Vicki Oladoyin, DO1, Brian Xu, MD1, Shanelle Brodeur, MD1, Abisola S. Ajayi, MD1, Emmanuel Marfo, MD1, Shaikhoon Mohammed, MD1, Christopher Fay, DO1, Chima Amadi, MD1, Nicolas Bakinde, MD1
1Moorehouse School of Medicine, Atlanta GA
|
| |
|
|
|
|
|
